Month: March 2026

VivoPower Announces New Stock Ticker “VIVO” and Corporate Name Change in Alignment with its Business Focus on AI Data Centers

Written by Customer Service on March 10, 2026. Posted in Public Companies.

LONDON, March 10, 2026 (GLOBE NEWSWIRE) — VivoPower International PLC (Nasdaq: VVPR) (“VivoPower” or the “Company”), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that, effective March 16, 2026, before the open of trading on the Nasdaq stock market, its stock will be traded under the ticker “VIVO”. The Company has also changed its name to VivoPower PLC. Both changes reflect the Company’s business focus on building, owning, and leasing powered land and data center infrastructure for AI compute applications. The name change does not affect the rights of shareholders, and no action is required from current shareholders. VivoPower’s scope is land, power, and real-estate infrastructure, with technology and operations...

Silynxcom Receives Approximately $100,000 Order for Elite Military Units in the Middle East

Written by Customer Service on March 10, 2026. Posted in Public Companies.

Netanya, Israel, March 10, 2026 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, today announced that it has received two purchase orders for approximately $100,000 from elite military units in the Middle East for the Company’s maintenance services. The current service orders are part of a framework contract with these customers and follow previous orders placed by these units for the Company’s advanced tactical systems. The Company continues to solidify its position among leading defense organizations and elite units seeking advanced and innovative tactical equipment for defense and communication. Silynxcom’s tactical systems provide combat-proven awareness and seamless radio connectivity in some of the world’s...

DrChrono Expands AI Capabilities with Launch of EverHealth Scribe Ambient Documentation Solution

Written by Customer Service on March 10, 2026. Posted in Public Companies.

EverHealth Scribe users report saving an average of 8 minutes of clinical documentation time per visit and 32% increase in same-day claim submissions DENVER, March 10, 2026 (GLOBE NEWSWIRE) — EverCommerce’s (Nasdaq: EVCM) healthcare business unit EverHealth today announced the launch of EverHealth Scribe, a new AI-powered ambient documentation technology embedded in DrChrono by EverHealth, an all-in-one Electronic Health Record (EHR) platform. EverHealth Scribe is designed to reduce the burden of clinical documentation by listening to provider–patient conversations and automatically generating compliant, structured visit notes within the EHR, ready for provider review and approval. “This launch reflects our commitment to delivering smarter, AI-powered solutions that focus on creating tangible provider and patient outcomes,” said...

Monroe Capital Corporation Announces $13.0 Million Increase in Special Pre-Merger Closing Distribution for Monroe Capital Corporation Stockholders Resulting in a $15.9 Million ($0.75 per share) Total Pre-Merger Closing Distribution

Written by Customer Service on March 10, 2026. Posted in Mergers And Acquisitions.

Horizon Technology Finance Corporation Announces Intent to Supplement Regular Monthly Distributions for Combined Company Stockholders for Two Quarters Following Closing of the Merger CHICAGO, March 10, 2026 (GLOBE NEWSWIRE) — Monroe Capital Corporation (NASDAQ: MRCC) (“MRCC”) today announced its intent to increase the amount of its final special distribution payable to legacy MRCC stockholders of record as of a time prior to the closing of its previously announced merger (the “Merger”) with Horizon Technology Finance Corporation (“HRZN”) by $13.0 million ($0.61 per share), contingent upon MRCC stockholder approval of the Merger and related closing conditions. As previously announced, following the Merger, HRZN will be the surviving public entity and will continue to be managed by Horizon Technology Finance Management LLC (“HTFM”)...

Transcontinental Inc. Announces Results for the First Quarter of Fiscal Year 2026

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

HighlightsRevenues of $263.5 million for the quarter ended January 25, 2026; operating earnings of $8.2 million; and net loss from continuing operations of $0.2 million (0.00 $ per share). Adjusted operating earnings before depreciation and amortization(1) of $33.1 million for the quarter ended January 25, 2026; adjusted operating earnings(1) of $17.5 million; and adjusted net earnings from continuing operations(1) of $6.7 million ($0.08 per share). Subsequent to the closing of the first quarter of fiscal year 2026, announcement of the closing of the sale of the Packaging Business. Appointment of Sam Bendavid as Chief Executive Officer, effective April 6, 2026.(1) Please refer to the “Non-IFRS Financial Measures” section of this press release for a definition of these measures. MONTRÉAL, March 10, 2026 (GLOBE NEWSWIRE)...

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Written by Customer Service on March 10, 2026. Posted in Public Companies.

Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD,...

SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

Strong growth in SSi Mantra installations, procedures and revenues FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026. Fourth Quarter 2025 OverviewRevenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024. Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024. Gross profit rose 60.7% to $6.4 million...

Public Inc. Acquires Rocket Social Impact, Accelerating U.S. Growth and Expanding Integrated Social Impact Capabilities

Written by Customer Service on March 10, 2026. Posted in Mergers And Acquisitions.

New York and Toronto, March 10, 2026 (GLOBE NEWSWIRE) — Public Inc., a North American B Corp and creative social impact agency, today announced the acquisition of Rocket Social Impact, a U.S.-based advisory firm known for its impact strategy and delivery-focused work with nonprofit and corporate social impact organizations. The acquisition strengthens and expands Public’s U.S. footprint and deepens its ability to deliver integrated strategy and execution to purpose-driven clients across North America. “We continue to believe in the immense opportunity for purpose-driven organizations in the North American market right now,” said Phil Haid, CEO of Public Inc. “Organizations are under pressure to demonstrate real impact, not just intention, and our goal is to grow our presence in the U.S. Rocket brings disciplined, implementation-driven...

VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.

Written by Customer Service on March 10, 2026. Posted in Mergers And Acquisitions.

Transaction Delivers Wholly Owned, Scalable Asset-Backed, Aviation Platform with Accelerating Revenue and Consolidated Control Positions VTAK at the Center of High-Growth Regional Air Mobility Ahead of Industry-Wide eVTOL Commercialization FORT MILL, S.C., March 10, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) today announced that it has completed the acquisition of the remaining 80.02% equity interest in Fly Flyte, Inc. (“Flyte”) from Creatd, Inc. (OTCQB: CRTDD), resulting in 100% ownership of the AI-enabled regional aviation operator. The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the owner of a revenue-generating, asset-backed aviation platform with certified aircraft, tangible infrastructure, and scalable fleet economics. Full...

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Written by Customer Service on March 10, 2026. Posted in Earnings Releases And Operating Results.

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 On track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations (LMs); regulatory update expected in 1H 2026 Expect to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 2H 2026 Completed oversubscribed $86 million public offering with participation from new and existing investors Cash, cash equivalents and investments of approximately...

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals